Overview

• Ovatools estimates an individual's ovarian cancer risk by combining a CA125 blood-test result with age for use in primary care.
• Two British Journal of Cancer studies, including analysis of roughly 340,000 women, report strong performance, particularly in those over 50.
• Economic modelling in a companion study suggests the approach would likely be cost-effective for NHS use.
• Researchers note current practice often relies on a single CA125 cut-off before referral for imaging, which may miss age-related risk variation.
• Cancer Research UK and NIHR leaders welcomed the evidence yet called for prospective, real-world evaluation before any NHS rollout.